Eurogentec demonstrates fermentation scalability of RBPS minicircle technology

Company

Eurogentec is the first CDMO to demonstrate that the fermentation process used in the RBPS minicircle technology is scalable and ready for use in the cGMP production of minicircle plasmid DNA.

A manuscript summarizing these results is now available on bioRxiv doi:10.1101/300236. 

About Reduced Backbone Plasmids

Minicircle plasmid technology aims to reduce plasmid DNA sequences to the most essential elements. Biopharmaceutical minicircle plasmids are devoid of antibiotic resistance markers and regulatory bacterial elements as these do not bring any therapeutic value in the prevention or treatment of disease and at the same time preserve the therapeutically relevant sequence elements. The resulting minicircle plasmid DNA not only removes potentially unsafe sequences from the plasmid DNA but also results in higher transfection and expression rates.

Trending Now

Kaneka Eurogentec completes commercial mRNA GMP facility expansion

Previous post

Kaneka Eurogentec receives GMP accreditation for its new state-of-the-art facility in time for the production of DNA vaccines against COVID-19

Next post

Recommended for you

Kaneka Eurogentec completes commercial mRNA..

Company

Newly accredited GMP facility for commercial manufacturing of mRNA in anticipation of customer BLA submission....
Continue Reading
24-25 March 2026

Nextgen Biomed

London, UK

Meet Eurogentec at "Nextgen Biomed"

@ London, UK
📅March 24-25, 2026
📍London (UK) - Booth #61
...
Continue Reading
17-20 November 2025

Medica

Düsseldorf, DE

Meet our team at "Medica"

@ Düsseldorf, DE
📅 November 17-20, 2025
📍Dusseldorf (DE) - AWEX Belgian Pavilion (Hall 15)
...
Continue Reading